Vericel Corporation
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About
CEO
Mr. Dominick C. Colangelo Esq.
Employees
314
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
64 Sidney Street, Cambridge, MA 02139, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 26, 2025 | 0.31 | — | — | — |
| Nov 7, 2024 | -0.05 | -0.02 | 0.03 | -60.00% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 5 |
| Average estimate | — | 0.02 | — | 0.47 |
| Low estimate | — | -0.04 | — | 0.35 |
| High estimate | — | 0.05 | — | 0.61 |
| Last year EPS | — | -0.08 | — | 0.16 |
[stock_revenue_estimate]
Growth estimates
Current qtr
30.770%
Next qtr. (Mar 2025)
141.660%
Current year
328.570%
Next year (Dec 2025)
192.190%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 197.52M | 164.37M | 156.18M | 124.18M | 117.85M |
| Cost of revenue | 61.94M | 54.58M | 50.16M | 39.95M | 37.57M |
| Gross profit | 135.58M | 109.79M | 106.03M | 84.23M | 80.28M |
| Operating expense | |||||
| Research & development | 21.04M | 19.94M | 16.29M | 13.02M | 30.39M |
| Selling general and admin | 121.00M | 106.90M | 97.59M | 68.84M | 61.14M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -6.46M | -17.06M | -7.85M | 2.37M | -11.25M |
| Non operating interest income | |||||
| Income | 4.63M | 1.34M | 224,000 | 691,000 | 1.61M |
| Expense | 600,000 | 366,000 | 4,000 | 6,000 | 8,000 |
| Other income expense | 64,000 | 95,000 | 52,000 | -13,000 | -20,000 |
| Pretax income | -2.37M | -15.99M | -7.58M | 3.04M | -9.67M |
| Tax provision | 814,000 | 721,000 | -111,000 | 180,000 | — |
| Net income | -3.18M | -16.71M | -7.47M | 2.86M | -9.67M |
| Basic EPS | -0.07 | -0.35 | -0.16 | 0.06 | -0.22 |
| Diluted EPS | -0.07 | -0.35 | -0.16 | 0.06 | -0.22 |
| Basic average shares | 47.59M | 47.13M | 46.47M | 45.22M | 44.18M |
| Diluted average shares | 47.59M | 47.13M | 46.47M | 45.22M | 44.18M |
| EBITDA | 2.86M | -11.64M | -4.61M | 5.43M | -7.91M |
| Net income from continuing op. | -3.18M | -16.71M | -7.47M | 2.86M | -9.67M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 353.66M | 273.00M | 243.71M | 205.61M | 153.24M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 69.09M | 51.07M | 68.33M | 33.62M | 26.89M |
| Other short term investments | 40.47M | 68.47M | 35.07M | 42.19M | 42.83M |
| Accounts receivable | 58.36M | 46.54M | 37.44M | 34.50M | 32.17M |
| Other receivables | — | — | — | — | — |
| Inventory | 13.09M | 15.99M | 13.38M | 9.36M | 6.82M |
| Prepaid assets | — | — | — | — | — |
| Restricted cash | 17.78M | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 6.85M | 4.80M | 4.25M | 3.89M | 2.95M |
| Non current assets | |||||
| Properties | 73.46M | 41.57M | 45.79M | 50.22M | 25.25M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 16.41M | 14.98M | 13.84M | 11.33M | 10.10M |
| Construction in progress | 32.53M | 5.44M | 3.10M | 2.02M | 859,000 |
| Leases | 14.90M | 13.69M | 10.62M | 5.56M | 5.26M |
| Accumulated depreciation | -22.21M | -18.30M | -14.32M | -11.39M | -9.22M |
| Goodwill | 6.88M | 7.50M | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 25.28M | 19.96M | 25.69M | 24.10M | 9.25M |
| Other non current assets | 771,000 | 1.30M | 528,000 | 211,000 | 89,000 |
| Total liabilities | 127.71M | 80.73M | 73.24M | 71.35M | 42.15M |
| Current liabilities | |||||
| Accounts payable | 22.35M | 16.93M | 9.02M | 6.76M | 6.35M |
| Accrued expenses | 3.96M | 5.96M | 4.12M | 2.09M | 1.05M |
| Short term debt | 6.19M | 4.30M | 2.99M | 4.44M | 5.50M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 13.26M | 10.23M | 9.92M | 9.20M | 6.90M |
| Other current liabilities | — | 41,000 | — | — | — |
| Non current liabilities | |||||
| Long term debt | 81.86M | 43.27M | 47.19M | 48.87M | 22.35M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 100,000 | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 629.23M | 593.25M | 553.90M | 510.06M | 489.75M |
| Retained earnings | -403.18M | -400.00M | -383.29M | -375.82M | -378.68M |
| Other shareholders equity | -100,000 | -978,000 | -154,000 | 14,000 | 21,000 |
| Total shareholders equity | 225.95M | 192.27M | 170.46M | 134.26M | 111.09M |
| Additional paid in capital | — | — | — | — | — |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||
| Net Income | -3.18M | -16.71M | -7.47M | 2.86M | -9.67M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.67M | -14.56M | -15.95M | -20.13M | -17.59M | -16.48M | -11.81M | -10.49M | -9.58M | -7.94M | -5.93M | -9.39M | -11.00M | -17.20M | -14.30M | -9.90M |
| Depreciation | 4.63M | 3.98M | 2.97M | 2.38M | 1.74M | 1.43M | 1.61M | 1.89M | 1.59M | 752,000 | 489,000 | 649,000 | 647,000 | 592,000 | 704,000 | 732,000 | -47,000 | 191,000 | 99,000 | 125,000 | 119,000 | 126,000 | 102,000 | 325,000 | 200,000 | 400,000 | 500,000 | 400,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 32.33M | 37.18M | 34.32M | 13.84M | 13.18M | 7.22M | 2.68M | 2.50M | 2.75M | 839,000 | 926,000 | 3.61M | 3.74M | 710,000 | 1.36M | 1.60M | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 6.32M | 4.33M | 4.43M | 4.54M | 2.83M | — | -13,000 | 1.75M | -80,000 | — | — | — | -29.00M | — | — | 1.60M | 2.81M | 1.07M | — | — | — | — | — | — | — | — | — | -100,000 |
| Accounts Receivable | -11.82M | -9.10M | -2.93M | -2.34M | -8.71M | -5.18M | -1.18M | -6.17M | -2.73M | -8.14M | — | — | 16,000 | 42,000 | -40,000 | 60,000 | 61,000 | 15,000 | 42,000 | 100,000 | -249,000 | 9,000 | 113,000 | -129,000 | 100,000 | 38,000 | -100,000 | — |
| Accounts Payable | 3.05M | 1.44M | 1.49M | 33,000 | -1.02M | 899,000 | -1.36M | -1.08M | 1.73M | 2.77M | -571,000 | 284,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | 3.78M | -5.69M | -7.46M | -7.42M | -5.94M | -1.24M | 260,000 | -1.02M | 354,000 | 14,000 | 172,000 | -366,000 | 52,000 | 404,000 | 591,000 | -541,000 | -685,000 | 1.13M | 424,000 | 80,000 | -181,000 | -880,000 | -790,000 | 184,000 | -1.06M | -80,000 | 200,000 | -400,000 |
| Operating Cash Flow | 35.11M | 15.44M | 25.34M | 13.91M | -7.59M | -5.01M | -15.29M | -21.70M | -12.73M | -23.68M | -14.61M | -25.30M | -44.21M | -12.81M | -13.33M | -16.68M | -15.46M | -14.07M | -11.25M | -10.18M | -9.89M | -8.68M | -6.50M | -9.01M | -11.76M | -16.84M | -13.70M | -10.00M |
| Investing Activities | ||||||||||||||||||||||||||||
| Capital Expenditures | — | — | -7.92M | -2.63M | -2.62M | -2.68M | -1.51M | -1.42M | -2.43M | -829,000 | -40,000 | -273,000 | -1.03M | -120,000 | -35,000 | -215,000 | -1.06M | -789,000 | -586,000 | -157,000 | -119,000 | -153,000 | -58,000 | -136,000 | -100,000 | -200,000 | -400,000 | -400,000 |
| Net Intangibles | -7.50M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | -1.45M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -55.23M | -69.55M | -60.02M | -63.06M | -72.35M | -66.55M | — | — | — | — | — | — | — | -5.00M | — | -30.70M | -49.38M | -43.90M | -25.94M | — | — | -5.50M | -1.50M | -10.66M | -1.00M | -12.30M | -19.20M | — |
| Sale of Investments | 79.61M | 40.94M | 64.44M | 48.52M | 85.58M | 2.20M | — | — | — | — | — | — | — | — | 6.00M | 40.00M | 69.00M | 28.08M | 8.00M | — | 1.00M | 4.50M | 12.25M | — | 10.20M | 18.50M | 4.20M | 8.50M |
| Investing Cash Flow | 24.38M | -28.61M | -3.50M | -17.16M | 10.62M | -67.03M | -1.51M | -1.42M | -2.39M | -2.18M | -40,000 | -273,000 | -1.03M | -5.12M | 5.97M | 9.08M | 18.56M | -16.61M | -18.52M | -157,000 | 881,000 | -1.15M | 10.69M | -10.80M | 9.10M | 5.90M | -15.40M | 8.10M |
| Financing Activities | ||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | 14.79M | 12.71M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | -17.53M | -8.04M | -2.44M | -35,000 | -8,000 | -34,000 | -40,000 | -227,000 | -479,000 | -445,000 | -356,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -2.38M | -2.61M | -2.01M | -191,000 | -26,000 | -710,000 | -613,000 | -213,000 | — | — | — | — | — | 277,000 | 259,000 | 241,000 | -777,000 | — | — | — | — | — | — | — | — | -100,000 | — | 3.60M |
| Financing Cash Flow | 3.62M | 1.05M | 9.17M | 6.44M | 5.26M | 51.79M | 6.14M | 40.01M | -24,000 | 49.93M | 14.40M | 37.93M | -195,000 | 17.32M | 8.35M | 13.50M | -80,000 | 24.76M | 27.07M | 16.10M | 10.02M | 7.85M | 4.27M | 12.21M | 7.60M | 9.91M | 19.90M | 9.60M |
| Other Cash Details | ||||||||||||||||||||||||||||
| End Cash Position | 86.87M | 51.07M | 68.54M | 33.83M | 26.98M | 18.29M | 26.86M | 22.98M | 14.58M | 30.34M | 8.06M | 13.64M | 5.53M | 14.12M | 17.00M | 16.49M | 13.44M | 9.03M | 14.41M | 16.93M | 10.51M | 8.61M | 10.66M | 2.06M | 7.50M | 2.10M | 1.90M | — |
| Income Tax Paid | 1.17M | — | 379,000 | 147,000 | 80,000 | — | 100,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 383,000 | 109,000 | 4,000 | 6,000 | 8,000 | 2.23M | 931,000 | 226,000 | — | — | 11,000 | 13,000 | 16,000 | 40,000 | 73,000 | 84,000 | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 7.80M | 10.09M | 21.13M | 14.95M | -9.80M | -3.09M | -14.69M | -21.31M | -15.77M | -26.24M | -19.98M | -29.82M | -25.52M | -15.21M | -13.84M | -19.74M | -15.89M | -14.31M | -11.65M | -9.68M | -9.11M | -8.90M | -6.42M | -7.01M | -11.30M | -15.80M | -13.70M | -9.50M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 3,177,602 | 196.38M | 6.44% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,521,587 | 94.03M | 3.08% |
| Brown Capital Management Small Company Fund | Sep 30, 2024 | 1,517,185 | 93.76M | 3.07% |
| Conestoga Small Cap Fund | Sep 30, 2024 | 1,473,225 | 91.05M | 2.98% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,362,231 | 84.19M | 2.76% |
| Fidelity Small Cap Growth Fund | Oct 31, 2024 | 827,737 | 51.15M | 1.68% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 744,610 | 46.02M | 1.51% |
| Professionally Managed Portf-Congress Small Cap Growth Fd | Nov 30, 2024 | 700,000 | 43.26M | 1.42% |
| Delaware Ivy Small Cap Growth Fund | Sep 30, 2024 | 644,612 | 39.84M | 1.31% |
| Loomis Sayles Small Cap Growth Fund | Sep 30, 2024 | 605,535 | 37.42M | 1.23% |
Article
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Feb 3, 2025
Article
Vericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Feb 3, 2025
Article
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.
Jan 15, 2025
